Stay updated with breaking news from Trial Application. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
ACTengine® IMA203 TCR-T monotherapy against PRAME showed 50% confirmed objective response rate (cORR) at or above target dose in different solid cancers in an interim clinical update in Phase 1a and Phase
Last patient dosed in Phase IIa trial for lead product candidate, SPL026 with supportive therapy for the treatment of Major Depressive Disorder Completion...
CTA1 approval by the ANSM2 and the EC3 of the phase 1 program resulting from the collaboration between Servier and Oncodesign Precision Medicine for the development of an innovative treatment in Parkinson's
Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Toronto, ON (PRWEB) May 26, 2022 -- The European Union Clinical Trial Regulation (EU CTR) is the largest change in the EU clinical trial landscape in 20